Milestone Pharma gains on FDA approval of nasal spray for patients with heart condition
ReutersDec 15, 2025 1:33 PM
Shares of Milestone Pharmaceuticals MIST.O surge 34.02% to $3.23 premarket
U.S. Food and Drug Administration on Friday approved Milestone's first commercial product, Cardamyst, a nasal spray for adults with a heart condition
The spray is designed to rapidly resolve episodes of paroxysmal supraventricular tachycardia - a type of irregular heartbeat - and restore sinus rhythm
The spray is expected to be available in retail pharmacies in Q1 2026
Up to last close, stock up 2% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
US November Non-Farm Payrolls and CPI data both loom【The week ahead】
TradingKey - On the equities front, Micron Technology, Nike, Accenture, FedEx, and other companies will release earnings. Following significant volatility in AI-related stocks, Micron Technology's earnings performance is receiving particular market attention.TradingKey
15 hours ago
Netflix Stock Analysis: Why Netflix Stock Keeps Falling, and When Should Investors Buy Netflix Stock?
While the final terms for Netflix's acquisition of WBD remain uncertain in the short term, we view the recent decline, driven by market sentiment, as a significant long-term undervalued opportunity. The return to more realistic valuations enhances the investment appeal of Netflix stock.TradingKey
15 hours ago
Musk Confirms SpaceX 2026 IPO: The Dual ‘Trillion-Dollar’ Bet with Hidden Risks
TradingKey - Elon Musk has confirmed speculation that his space exploration company, SpaceX, is preparing for an IPO as early as 2026. The potential listing, which could value SpaceX at over $1 trillion, might catapult it into the ranks of the world's top ten most valuable companies. This raises aTradingKey
Thu, Dec 11
Gold Price Steady Climb and the Sudden Surge of Silver and Copper: Will Their Bull Run Extend Into 2026?
Dow Jones Market Data shows this marks the first time since 1980all three metals—gold, silver, and copper—simultaneously refreshed their all-time highs in the same year. Will this rally extend into 2026?TradingKey
Wed, Dec 10
Why Did Strategy's Stock Price Plummet? Can MSTR Reach $1,000?
MicroStrategy (MSTR) stock, despite pressures from Bitcoin volatility and its weak core business, represents the most leveraged investment in a Bitcoin bull market. The company's stock path to $1,000 largely depends on Bitcoin's market performance. Major institutions, including Standard Chartered anTradingKey
Thu, Dec 4
Tradingkey
